Antimalarial medication

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Retrieved on: 
Tuesday, April 9, 2024
Antimalarial medication, Polyene, Fungal infection, Candidiasis, Congress, Biotechnology, Azole, Candida auris, Patient, Mouse, Infection, University, NOS, Echinocandin, University of Texas System, Fluconazole, ECCMID, European, Candida glabrata, Pharmaceutical industry

These presentations at ECCMID 2024 continue to build upon SCY-247’s positive preclinical data illustrating its unique attributes in the fight against difficult-to-treat fungal infections.

Key Points: 
  • These presentations at ECCMID 2024 continue to build upon SCY-247’s positive preclinical data illustrating its unique attributes in the fight against difficult-to-treat fungal infections.
  • Candida auris is an emerging fungal pathogen associated with nosocomial infections and considered a serious global health threat.
  • The work here utilized the National Institute of Allergy and Infectious Diseases’ (NIAID’s) suite of preclinical services for in vivo testing (Contract Nos.
  • SCY-247, a novel second-generation IV/oral triterpenoid antifungal, demonstrates in vitro activity against fungal pathogens, including azole-resistant strains of Candida and Aspergillus

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Antimalarial medication, Research, FURI, Congress, Conference, Biotechnology, TIMM, Aspergillosis, GSK, Sale, Mucorales, LAMB, National Institutes of Health, NIH, Trial of the century, IND, AAAM, Investment, Data analysis, Medical Mycology, Pharmaceutical industry

“SCY-247 continues to demonstrate highly encouraging preclinical results, with potent activity against a broad range of fungal pathogens, including mucormycosis.

Key Points: 
  • “SCY-247 continues to demonstrate highly encouraging preclinical results, with potent activity against a broad range of fungal pathogens, including mucormycosis.
  • In March 2023, SCYNEXIS and GSK entered into an exclusive license agreement for the development, manufacturing and commercialization of ibrexafungerp (BREXAFEMME).
  • Presented preclinical data on SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) held in Athens, Greece October 20-23, 2023.
  • Cash, cash equivalents and investments totaled $98.0 million on December 31, 2023, compared to $73.5 million on December 31, 2022.

New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection

Retrieved on: 
Tuesday, February 20, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Hospitals, Clinical Trials, Senior, Urinary tract infection, Infection, Multimedia, MDR, MD, Physician, Marketing, Antimalarial medication, Klebsiella pneumoniae, Pyelonephritis, NEJM, Safety, Therapy, Patient, UTI, AP, Melinta Therapeutics, Medication, Pseudomonas aeruginosa, Fungal infection, Pharmaceutical industry

Venatorx Pharmaceuticals, Melinta Therapeutics LLC (“Melinta”), and Menarini Group today announced that The New England Journal of Medicine (NEJM) published the results of the CERTAIN-1 Phase 3 clinical study of the investigational agent cefepime-taniborbactam for the treatment of adult patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), including those with bacteremia.

Key Points: 
  • Venatorx Pharmaceuticals, Melinta Therapeutics LLC (“Melinta”), and Menarini Group today announced that The New England Journal of Medicine (NEJM) published the results of the CERTAIN-1 Phase 3 clinical study of the investigational agent cefepime-taniborbactam for the treatment of adult patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), including those with bacteremia.
  • The results showed that cefepime-taniborbactam was superior to meropenem for the treatment of complicated UTI that included acute pyelonephritis, with a similar safety profile to meropenem.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240220917017/en/
    “Gram-negative infections such as cUTI have become increasingly difficult to treat due to acquired bacterial resistance to multiple classes of antibiotics.

Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes benefitting society in 2023

Retrieved on: 
Wednesday, March 6, 2024
Novo Nordisk Foundation, Research, Biotechnology, DKK, Antimalarial medication, Education, Investment, Food, Partnership, NIVI, Vaccine, University, Health, Climate change, Novo Holdings A/S, CO2, Protein, Tuberculosis, Science, Agriculture, Bill, Human

In 2023, the Foundation awarded more than DKK 9.1 billion, in philanthropic grants and investments, and supported a total of 751 new projects.

Key Points: 
  • In 2023, the Foundation awarded more than DKK 9.1 billion, in philanthropic grants and investments, and supported a total of 751 new projects.
  • One of its largest mission-driven initiatives in 2023 was the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI), a research and vaccine development initiative launched in partnership with the University of Copenhagen.
  • The DKK 9.1 billion awarded in 2023 marks an increase in grant giving from previous years.
  • The Novo Nordisk Foundation Cellerator, a world-class facility for developing and upscaling cell therapies for testing in humans.

Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes benefitting society in 2023

Retrieved on: 
Wednesday, March 6, 2024
Novo Nordisk Foundation, Research, Biotechnology, DKK, Antimalarial medication, Education, Investment, Food, Partnership, NIVI, Vaccine, University, Health, Climate change, Novo Holdings A/S, CO2, Protein, Tuberculosis, Science, Agriculture, Bill, Human

In 2023, the Foundation awarded more than DKK 9.1 billion, in philanthropic grants and investments, and supported a total of 751 new projects.

Key Points: 
  • In 2023, the Foundation awarded more than DKK 9.1 billion, in philanthropic grants and investments, and supported a total of 751 new projects.
  • One of its largest mission-driven initiatives in 2023 was the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI), a research and vaccine development initiative launched in partnership with the University of Copenhagen.
  • The DKK 9.1 billion awarded in 2023 marks an increase in grant giving from previous years.
  • The Novo Nordisk Foundation Cellerator, a world-class facility for developing and upscaling cell therapies for testing in humans.

SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference

Retrieved on: 
Tuesday, January 30, 2024
Biotechnology, Antimalarial medication, Conference

JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will present at Guggenheim’s 6th Annual Biotechnology Conference on Wednesday, February 7 at 11:00 A.M.

Key Points: 
  • JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will present at Guggenheim’s 6th Annual Biotechnology Conference on Wednesday, February 7 at 11:00 A.M.
  • ET.

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Retrieved on: 
Monday, January 29, 2024
Mortality, Patient, Leukemia, LAMB, Therapy, MD, FCCP, Infection, Biotechnology, Survival, Fungal infection, COVID, FAAM, Aspergillosis, Division, Immunodeficiency, Conference, Bone marrow, UCLA, Transplant, B♭ (musical note), Doctor of Philosophy, Antimalarial medication, FIDSA, Harbor–UCLA Medical Center, Lung, AAAM, Diabetes, Pharmaceutical industry

In this highly lethal mouse model of mucormycosis, SCY-247 showed very promising in vivo efficacy.

Key Points: 
  • In this highly lethal mouse model of mucormycosis, SCY-247 showed very promising in vivo efficacy.
  • This is comparable to the 40% survival observed in the control group treated with 10 mg/kg of intravenous standard of care of liposomal amphotericin B (LAMB) (p = 0.008 vs. placebo).
  • The combination treatment of SCY-247 plus LAMB demonstrated the greatest reduction in fungal burden and was highly statistically significant in both lung and brain tissue (both p
  • “These positive data continue to accumulate and define the unique properties of SCY-247, highlighting its potential to be differentiated from currently available antifungals.

Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections

Retrieved on: 
Tuesday, January 9, 2024
Senior, Death, Mortality, World Health Organization, Immunity, Patient, Infection, Research, Drug resistance, Parasitism, Novo Nordisk Foundation, Pipeline, Society, Partnership, World Bank, Civil service commission, European Commission, CDC, G7, Bacteria, Investment, Disease, HIV/AIDS, USD, Urinary tract infection, Virus, Antimalarial medication, Malaria, Vaccine, REPAIR, AMR, Fungus, Food chain, Boston University, Pharmaceutical industry

"Like CARB-X, the Novo Nordisk Foundation is committed to driving innovation in the fight against drug-resistant infections," says Peter Lawætz Andersen, Senior Vice President, Infectious Diseases at the Foundation.

Key Points: 
  • "Like CARB-X, the Novo Nordisk Foundation is committed to driving innovation in the fight against drug-resistant infections," says Peter Lawætz Andersen, Senior Vice President, Infectious Diseases at the Foundation.
  • The grant is also part of a broader commitment from the Foundation and Novo Holdings to fight drug resistance through the development of innovative products.
  • The Foundation is also funding a major new initiative – the Novo Nordisk Foundation Initiative for Vaccines and Immunity – that will reduce the use of antibiotics and thus the spread of AMR by developing vaccines against respiratory infections.
  • With this grant, the Novo Nordisk Foundation joins major governments and foundations in supporting the work of CARB-X.

Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections

Retrieved on: 
Tuesday, January 9, 2024
Senior, Death, Mortality, World Health Organization, Immunity, Patient, Infection, Research, Drug resistance, Parasitism, Novo Nordisk Foundation, Pipeline, Society, Partnership, World Bank, Civil service commission, European Commission, CDC, G7, Bacteria, Investment, Disease, HIV/AIDS, USD, Urinary tract infection, Virus, Antimalarial medication, Malaria, Vaccine, REPAIR, AMR, Fungus, Food chain, Boston University, Pharmaceutical industry

"Like CARB-X, the Novo Nordisk Foundation is committed to driving innovation in the fight against drug-resistant infections," says Peter Lawætz Andersen, Senior Vice President, Infectious Diseases at the Foundation.

Key Points: 
  • "Like CARB-X, the Novo Nordisk Foundation is committed to driving innovation in the fight against drug-resistant infections," says Peter Lawætz Andersen, Senior Vice President, Infectious Diseases at the Foundation.
  • The grant is also part of a broader commitment from the Foundation and Novo Holdings to fight drug resistance through the development of innovative products.
  • The Foundation is also funding a major new initiative – the Novo Nordisk Foundation Initiative for Vaccines and Immunity – that will reduce the use of antibiotics and thus the spread of AMR by developing vaccines against respiratory infections.
  • With this grant, the Novo Nordisk Foundation joins major governments and foundations in supporting the work of CARB-X.

Revagenix, Inc. Announces Series B Financing to Develop Novel Antibiotics and Additions to its Board of Directors

Retrieved on: 
Friday, January 5, 2024
Doctor of Pharmacy, Partnership, Infection, NIAID, Antimalarial medication, Hope, SAN, Doctor of Philosophy, COVID-19, Series, Growth, Patient, Management

"We are pleased and honored to have our new directors join the Revagenix board.

Key Points: 
  • "We are pleased and honored to have our new directors join the Revagenix board.
  • These additions will bolster and complement our leadership team's extensive experience in anti-infectives to address the scientific and commercial challenges in the field."
  • The Series B financing complements ongoing funding from two product development contracts with the National Institute of Allergy and Infectious Diseases (NIAID).
  • As part of this transition, two former directors, Andrew Calabrese and Aleks Engel will step down from the board.